Trial Profile
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ASPIRE
- Sponsors Amgen; Onyx Pharmaceuticals
- 01 Oct 2022 Results of post-hoc pooled analysis assessing cardiovascular risk factors and cardiovascular disease data from four clinical studies: ASPIRE, ARROW, FOCUS, ENDEAVOR published in the Clinical Lymphoma, Myeloma & Leukemia
- 08 Dec 2020 Results assessing eligibility criteria of 6 landmark multiple myeloma studies (SPIRE, TOURMALINE-MM1, POLLUX, ELOQUENT-2, CASTOR and ENDEAVOR), presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 10 Dec 2019 Results comparing the cost per progression-free survival (PFS) for each of the comparators from the perspective of the Brazilian private healthcare system using PFS values based on POLLUX, ASPIRE, TOURMALINE MM1 and ENDEAVOR trials presented at the 61st Annual Meeting and Exposition of the American Society of Hematology